KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Raw Materials (2016 - 2025)

Resmed (RMD) has disclosed Raw Materials for 16 consecutive years, with $374.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials rose 2.72% year-over-year to $374.7 million, compared with a TTM value of $374.7 million through Dec 2025, up 2.72%, and an annual FY2025 reading of $367.3 million, up 3.29% over the prior year.
  • Raw Materials was $374.7 million for Q4 2025 at Resmed, up from $363.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $468.8 million in Q1 2023 and bottomed at $145.4 million in Q1 2021.
  • Average Raw Materials over 5 years is $358.7 million, with a median of $366.0 million recorded in 2024.
  • The sharpest move saw Raw Materials skyrocketed 134.0% in 2022, then decreased 22.56% in 2024.
  • Year by year, Raw Materials stood at $322.6 million in 2021, then soared by 43.66% to $463.4 million in 2022, then rose by 0.82% to $467.2 million in 2023, then fell by 21.92% to $364.8 million in 2024, then rose by 2.72% to $374.7 million in 2025.
  • Business Quant data shows Raw Materials for RMD at $374.7 million in Q4 2025, $363.4 million in Q3 2025, and $367.3 million in Q2 2025.